SML0557
SC-514
≥97% (HPLC)
別名:
4-Amino-[2,3"]bithiophenyl-5-carboxylic acid amide
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
Quality Level
assay
≥97% (HPLC)
form
powder
color
white to light brown
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
SMILES string
[s]1c(cc(c1C(=O)N)N)c2c[s]cc2
InChI
1S/C9H8N2OS2/c10-6-3-7(5-1-2-13-4-5)14-8(6)9(11)12/h1-4H,10H2,(H2,11,12)
InChI key
BMUACLADCKCNKZ-UHFFFAOYSA-N
Application
SC-514 has been used to study its effect on lipopolysaccharide (LPS)-induced phosphorylation of NF-κB (nuclear factor-κB) p65 and p38 MAPK (mitogen-activated protein kinase).
Biochem/physiol Actions
SC-514 is a cell-permeable, potent and selective ATP competitive inhibitor of nuclear factor kappa-B kinase-2 (IKK-2) that specifically blocks NF-?B-dependent gene expression. SC-514 exhibits anti-inflammatory properties.
SC-514 is a cell-permeable, potent and selective ATP competitive inhibitor of nuclear factor kappa-B kinase-2 (IKK-2).
SC-514 is an amino-acetamide compound. It is selective for IKKβ with an IC50 value of 3−12 μM. SC-514 also inhibits cytokines such as interleukin-6 (IL-6) and IL-8, mediated by IKKβ. IKKβ is responsible for osteoclast survival, hence its inhibition affects osteogenesis.
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lipopolysaccharide-binding protein downregulates fractalkine through activation of p38 MAPK and NF-kappaB
Huang X, et al.
Mediators of Inflammation, 2017 (2017)
SC-514, a selective inhibitor of IKKbeta attenuates RANKL-induced osteoclastogenesis and NF-kappaB activation
Liu Q, et al.
Biochemical Pharmacology, 86(12), 1775-1783 (2013)
Wei You et al.
Aging, 11(11), 3574-3584 (2019-05-31)
Formation of aortic aneurysms as a consequence of augmented transforming growth factor β (TGF-β) signaling and vascular smooth muscle cell (VSMC) dysfunction is a potentially lethal complication of Marfan syndrome (MFS). Here, we examined VSMC senescence in patients with MFS